文献速递糖尿病

桑枝总生物碱片治疗2型糖尿病的多中心随机双盲双模拟平行对照试验

Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy, and Parallel Controlled Clinical Trial.
PubMed 文献 · Diabetes Care · 2021-04-08

本研究为多中心、随机、双盲、双模拟、平行对照非劣效性临床试验,为期24周,共纳入600例2型糖尿病患者,随机分配至桑枝总生物碱片组(n=360)或阿卡波糖组(n=240)。主要疗效终点为糖化血红蛋白(HbA1c)较基线的变化。结果显示,治疗24周后,桑枝总生物碱片组HbA1c变化为-0.93%(95%CI -1.03至-0.83),阿卡波糖组为-0.87%(95%CI -0.99至-0.76),两组最小二乘均值差为-0.05%(95%CI -0.18至0.07),协方差分析无显著差异(P>0.05)。桑枝总生物碱片组治疗相关不良事件和胃肠道疾病发生率显著低于阿卡波糖组(P<0.01),两组总体不良事件或严重不良事件无差异(P>0.05)。结论:桑枝总生物碱片在2型糖尿病患者中降糖效果与阿卡波糖相当,且治疗相关不良事件和胃肠道疾病发生率更低,提示安全性良好。

要点

  • 桑枝总生物碱片降HbA1c效果与阿卡波糖相当,组间差异无统计学意义。
  • 桑枝总生物碱片治疗相关不良事件和胃肠道疾病发生率显著低于阿卡波糖。
  • 两组总体不良事件和严重不良事件发生率无显著差异。

核心结论

  • 桑枝总生物碱片在2型糖尿病患者中降糖效果与阿卡波糖相当,且治疗相关不良事件和胃肠道疾病发生率更低,安全性良好。

研究设计与样本

  • 多中心、随机、双盲、双模拟、平行对照非劣效性临床试验,为期24周,共纳入600例2型糖尿病患者,随机分为桑枝总生物碱片组(n=360)和阿卡波糖组(n=240)。

主要发现

  • 治疗24周后,桑枝总生物碱片组HbA1c变化为-0.93%(95%CI -1.03至-0.83),阿卡波糖组为-0.87%(95%CI -0.99至-0.76)。
  • 两组HbA1c变化的最小二乘均值差为-0.05%(95%CI -0.18至0.07),协方差分析无显著差异(P>0.05)。
  • 桑枝总生物碱片组治疗相关不良事件和胃肠道疾病发生率显著低于阿卡波糖组(P<0.01)。
  • 两组总体不良事件或严重不良事件发生率无显著差异(P>0.05)。

临床怎么用

  • 对于2型糖尿病患者,桑枝总生物碱片可作为与阿卡波糖降糖效果相当的候选药物,且胃肠道不良反应更少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to evaluate the efficacy and safety of mulberry twig alkaloids (Sangzhi alkaloids [SZ-A]) in the treatment of type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: This was a multicenter, randomized, double-blind, double-dummy, and parallel controlled noninferiority clinical trial that was conducted for 24 weeks. A total of 600 patients were randomly allocated to the SZ-A group (n = 360) or acarbose group (n = 240). The primary efficacy end point was the change of glycosylated hemoglobin (HbA1c) compared with baseline. In addition, adverse events (AEs), severe AEs (SAEs), treatment-related AEs (TAEs), and gastrointestinal disorders (GDs) were monitored. RESULTS: After treatment for 24 weeks, the change in HbA1c was -0.93% (95% CI -1.03 to -0.83) (-10.2 mmol/mol [-11.3 to -9.1]) and -0.87% (-0.99 to -0.76) (-9.5 mmol/mol [-10.8 to -8.3]) in the SZ-A and acarbose groups, respectively, and the least squares mean difference was -0.05% (95% CI -0.18 to 0.07) (-0.5 mmol/mol [-2.0 to 0.8]) between the two groups, with no significant difference on the basis of covariance analysis (P > 0.05). The incidence of TAEs and GDs was significantly lower in the SZ-A group than the acarbose group (P < 0.01), but no differences for AEs or SAEs between the two groups were observed (P > 0.05). CONCLUSIONS: SZ-A exhibited equivalent hypoglycemic effects to acarbose in patients with T2D. Nevertheless, the incidence of TAEs and GDs was lower following SZ-A treatment than acarbose treatment, suggesting good safety.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Qu L, Liang X, Tian G, et al. Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy, and Parallel Controlled Clinical Trial. Diabetes Care. 2021. PMID: 33832957. doi:10.2337/dc20-2109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。